Phase II/III of Recombinant Human Serum Albumin
To Evaluate the Effectiveness of Recombinant Human Serum Albumin Versus Human Serum Albumin in Patients With Hepatic Cirrhosis and Safety of Random, Double-blind, Parallel Grouping Phase II/III Clinical Trial
Sponsor: Protgen Ltd
This PHASE2/PHASE3 trial investigates Cirrhotic Ascites and is currently completed. Protgen Ltd leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2/PHASE3
-
Oct 2025 — Mar 2026 [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Jul 2023 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
May 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Protgen Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changde, China , Changsha, China , Chenzhou, China , Foshan, China , Guangzhou, China , Hengyang, China , Jinan, China , Linfen, China , Nanchang, China and 8 more locations